share_log

BMO Capital Maintains Market Perform on Macrogenics, Lowers Price Target to $5

BMO Capital Maintains Market Perform on Macrogenics, Lowers Price Target to $5

BMO Capital维持对Macrogenics的市场表现评级,将其目标价降至5美元。
Benzinga ·  08/07 11:12  · 评级/大行评级

BMO Capital analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Market Perform and lowers the price target from $8 to $5.

BMO Capital分析师Etzer Darout 维持Macrogenics (纳斯达克:MGNX) 的市场表现,将目标价从$8降至$5。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发